Review

MicroRNAs: Important Regulatory Molecules in Acute Lung Injury/Acute Respiratory Distress Syndrome

Qianying Lu 1,2,*, Sifan Yu 1,2,*, Xiangyan Meng 1,2, Mingyu Shi 1,2, Siyu Huang 1,2, Junfeng Li 1,2, Jianfeng Zhang 1,2, Yangfan Liang 1,2, Mengjun Ji 1,2, Yanmei Zhao 1,2,* and Haojun Fan 1,2,*

1 Institute of Disaster and Emergency Medicine, Tianjin University, Tianjin 300072, China; qianying.lu@tju.edu.cn (Q.L.); yusifan@tju.edu.cn (S.Y.); mengxiangyan@tju.edu.cn (X.M.); shimingyu1997@tju.edu.cn (M.S.); 2019435008@tju.edu.cn (S.H.); lijunfeng@tju.edu.cn (J.L.); jianfeng_zhang@1231@tju.edu.cn (J.Z.); liangyangfan1@163.com (Y.L.); jimengjun2000@163.com (M.J.)
2 Tianjin Key Laboratory of Disaster Medicine Technology, Tianjin 300072, China

* Correspondence: zhaoyanmei@126.com (Y.Z.); haojunfan86@163.com (H.F.)
† These authors contributed equally to this work.

Abstract: Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) is an overactivated inflammatory response caused by direct or indirect injuries that destroy lung parenchymal cells and dramatically reduce lung function. Although some research progress has been made in recent years, the pathogenesis of ALI/ARDS remains unclear due to its heterogeneity and etiology. MicroRNAs (miRNAs), a type of small noncoding RNA, play a vital role in various diseases. In ALI/ARDS, miRNAs can regulate inflammatory and immune responses by targeting specific molecules. Regulation of miRNA expression can reduce damage and promote the recovery of ALI/ARDS. Consequently, miRNAs are considered as potential diagnostic indicators and therapeutic targets of ALI/ARDS. Given that inflammation plays an important role in the pathogenesis of ALI/ARDS, we review the miRNAs involved in the inflammatory process of ALI/ARDS to provide new ideas for the pathogenesis, clinical diagnosis, and treatment of ALI/ARDS.

Keywords: MicroRNAs; acute lung injury; acute respiratory distress syndrome; inflammation; biomarker

1. Introduction

Acute lung injury (ALI), a life-threatening condition, is caused by direct or indirect injury factors, such as sepsis, pneumonia, inhalation of stomach contents, invasion of epidemic viruses, trauma, blast, smoke inhalation and asphyxiant inhalation [1–7]. These injury factors activate immune cells, which subsequently initiate abnormal immune responses. Immune cells activated by injury factors release excessive proinflammatory factors, chemokines, and proteases, which ultimately damage lung parenchymal cells, such as vascular endothelial cells and alveolar epithelial cells [2]. When a large number of damaged lung parenchymal cells cause ventilation dysfunction, rapid attenuation of respiratory function occurs [2]. The characteristics of ALI include increased permeability of alveolar epithelial cells and capillary endothelial cells, diffuse pulmonary interstitial and alveolar edema, gas exchange disorders, and hypoxemia, which eventually lead to respiratory failure [8,9]. The clinical emergence of critical illness is mainly characterized by accelerated respiratory frequency, respiratory distress, and intractable hypoxemia. If not treated in time, it will develop into acute respiratory distress syndrome (ARDS) [10,11]. For the last 20 years, the mortality rate of ARDS has remained at approximately 40% [11,12]. In recent years, with the outbreak of acute infectious pneumonia caused by SARS-CoV and SARS-CoV-2, ALI and more serious ARDS have been one of the main causes of death [13,14]. Currently, no effective drug treatment is available to improve the survival of ALI/ARDS patients.

MicroRNAs (miRNAs) are a type of highly conserved single-stranded RNA with a length of approximately 22 nucleotides that are involved in the physiological and patho-
logical functions of a variety of diseases, including tuberculosis [15], ALI/ARDS [16], pulmonary fibrosis [17], hepatitis [18], cardiovascular diseases [18], and cancer [18]. MiRNAs mainly bind to the 3′-untranslated region (3′-UTR) of mRNA to control multiple pathways and various cellular processes, such as inflammatory-immune responses and cell-cell interactions [19]. At present, it is believed that excessively activated and recruited inflammatory cells in the lung produce a large number of proinflammatory factors, and their interaction with effector cells is the main pathophysiological change in ALI/ARDS [2,20,21]. As an important inflammatory regulator, miRNAs might play an important role in ALI/ARDS. Indeed, studies have found that miRNA expression abnormalities can be observed in ALI/ARDS. For example, a clinical trial study found that the expression of miR-150 is low in the serum of ARDS patients and is negatively correlated with the Acute Physiology and Chronic Health Evaluation (APACHE) II score, an indicator to assess the condition and prognosis of ICU patients [22]. Additionally, high miR-122 expression is related to the severity and prognosis of ARDS patients, and miR-122 combined with the APACHE II score has a high evaluation value for the prognosis of ARDS patients [23]. Given that miRNAs play an important role in inflammation, which is a common feature of ALI/ARDS, miRNAs may be diagnostic indicators and therapeutic targets of ALI/ARDS [24]. This article reviews the miRNAs involved in the inflammatory process of ALI/ARDS to provide new ideas for the pathogenesis, clinical diagnosis, and treatment of ALI/ARDS.

2. Mechanisms Leading to Tissue Damage in ALI/ARDS

2.1. PRRs and Related Molecules in ALI/ARDS

Pattern recognition receptors (PRRs) are an important component of the first line of defense in the natural immune system [25] and play an essential role in the innate and adaptive immune responses of ALI/ARDS. PRRs are expressed by innate immune cells, such as natural killer cells (NK cells), macrophages, neutrophils, and dendritic cells, and mainly include transmembrane pattern recognition receptors (Toll-like receptors (TLRs) and C-type lectin receptors), cytoplasmic pattern recognition receptors (nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs)), retinoic acid-inducible gene I (RIG-I)-like receptors) and cytoplasmic DNA sensors, which can recognize pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs) [25]. PAMPs are mainly derived from exogenous molecules of pathogenic or nonpathogenic microorganisms, such as lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria, and viral double-stranded RNA (dsRNA) [26]. DAMPs refer to endogenous molecules released after body cells are damaged or die, such as high mobility histone B1 [26] and heat shock protein [26]. These are released after tissues or cells are stimulated via endogenous danger signals, including injury, hypoxia, and stress. Given the numerous reports on TLR and NLR related to ALI/ARDS, the following mainly introduces the structure and pathway of the two families.

2.1.1. TLRs

TLRs are a type of transmembrane protein that play an important role in the innate immune system and the inflammatory process [27]. TLRs are expressed in epithelial cells, dendritic cells, neutrophils, and macrophages and are widely distributed in various parts of the body [28]. TLRs recognize foreign pathogens or cell damage and play a key role in the immune response and the body’s resistance to foreign pathogens.

Studies have found that LPS can activate TLR4 and initiate the expression of downstream inflammatory response signaling pathways, which ultimately result in the release of the inflammatory factors IL-1β, IL-6, and TNF-α [29]. Current studies have confirmed that TLR4 is the most important PRR for recognizing LPS inflammatory signal transduction. Genetic inactivation of TLR4 can significantly attenuate ALI/ARDS [30].
2.1.2. NLRs

NLRs, a type of cytoplasmic pattern recognition receptor, play a unique regulatory role in innate immunity and adaptive immunity. Unlike TLRs that recognize PAMPs on the surface, NLRs are activated by the signals of PAMPs and DAMPs (such as changes in cell volume, rupture of lysosomes, production of reactive oxygen species (ROS), K$^+$ efflux, and Ca$^{2+}$ signaling [31]) inside the cell and form part of the inflammasome. Inflammasomes can activate caspase-1 and control the maturation and secretion of IL-1β and IL-18 [32]. The inflammasome mediates the occurrence and development of ALI, so targeted treatment of the inflammasome may represent an effective strategy to prevent and treat ALI.

2.2. Inflammation-Related Pathways of ALI/ARDS

2.2.1. TLRs Mediate NF-κB Signaling Pathway

Except for TLR3, all TLRs induce inflammation through the classic signaling of the MyD88-dependent signaling pathway. Myeloid differentiation factor 88 (MyD88) is a key adaptor of the Toll-like receptor/interleukin-1 receptor (TLR/IL-1 receptor, TIR) pathway [33]. This pathway is closely related to a conserved intracellular sequence of TLRs called TIR [34]. The activated TLR intracellular domain TIR binds to MyD88, and MyD88 binds to interleukin-1 receptor-associated kinase (IRAK), thereby inducing IRAK autophosphorylation. Phosphorylated IRAK1 can bind to and activate tumor necrosis factor receptor-associated factor 6 (TRAF6), which subsequently leads to nuclear factor kappaB (NF-κB) and activator protein-1 (AP-1) activation and eventually induces the expression and release of proinflammatory cytokines, such as IL-1, IL-6, IL-8, TNF-α, and chemokines [35,36] (Figure 1).

Among TLRs, current research has confirmed that TLR4 is the most important PRR that recognizes LPS inflammatory signal transduction. The TLR4-mediated NF-κB signaling pathway is closely related to the occurrence of ALI/ARDS [37]. Studies have shown that MyD88 gene knockout can inhibit NF-κB activation, downregulate the expression and release of TNF-α, and alleviate ALI/ARDS [33]. In addition, TLR4 can also activate the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to cell survival, growth, angiogenesis, and metabolism. TLR4 activation by LPS promotes PI3K and its downstream molecule protein kinase B (PKB, also known as AKT) to form a complex with MyD88, which subsequently leads to NF-κB activation [38]. Therefore, controlling the TLR-mediated NF-κB pathway can reduce the release of inflammatory mediators, which may represent a new effective treatment strategy for ALI/ARDS [39].

2.2.2. JAK2/STAT3 Signal Pathway

The Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway plays a key role in ALI/ARDS, and its activation is associated with IL-6 [40]. First, IL-6 binds to the receptor complex gp130/IL-6R on the surface of the host cell, thereby activating the JAK2/STAT3 signaling pathway. Then, the activated STAT3 dimer is transferred to the nucleus to initiate gene transcription [41], thereby regulating various activities (such as endothelial cell damage). Xu et al. [42] showed that in human pulmonary microvascular endothelial cells (HPMECs) and mouse macrophage Raw264.7 cell models induced by LPS, p-STAT3 inhibition reduces macrophage cytokine secretion and lung endothelial cell damage through the IL-6/JAK2/STAT3, NF-κB, and MAPK signaling pathways. Therefore, this pathway is involved in the occurrence and development of ALI/ARDS, and its regulation may provide effective treatment options for ALI/ARDS.
Figure 1. Inflammation-related pathways of ALI/ARDS. DC: dendritic cell; NK: natural killer cell; JAK2: Janus kinase 2; STAT3: signal transducer and activator of transcription 3; SCOS3: Suppressor of Cytokine Signaling 3; PI3K: phosphatidylinositol 3-kinase; AKT: protein kinase B (PKB, also known as AKT); mTOR: Mammalian Target of Rapamycin; TLR4: Toll-like receptor 4; MyD88: Myeloid differentiation factor 88; IRAK: interleukin-1 receptor-associated kinase; TRAF6: tumor necrosis factor receptor-associated factor 6; IKK: Ikappa B kinase; NF-κB: nuclear factor kappaB; AP-1: activator protein-1; NLRP3: NOD-like receptor thermal protein domain associated protein 3; ASC: apoptosis-associated speck-like protein containing a CARD; Pro-Caspase-1: pro-cysteinyl aspartate specific proteinase-1; Caspase-1: cysteinyl aspartate specific proteinase-1.

2.2.3. The Role and Signaling Pathway of the NLRP3 Inflammasome in ALI/ARDS

NLRP3 belongs to the NLR family and is the most studied NLR. The classical pathway of NLRP3 inflammasome activation depends on the TLR4 signaling pathway and is mediated by the interaction of the first signal provided by PAMPs and the second signal provided by DAMPs. The first signal is mediated by microbial molecules or endogenous cytokines and then activates the TLR4/NF-κB signaling pathway, which subsequently upregulates the expression of NLRP3, pro-IL-18, and pro-IL-1β. The second signal is mediated by DAMPs; after NLRP3 recognizes PAMPs or DAMPs, it oligomerizes and recruits connexin ASC and caspase-1 precursors (pro-Caspase-1) for assembly into NLRP3 inflammasome, which leads to the maturation and activation of pro-Caspase-1 by self-cleavage [43]. Activated Caspase-1 also rapidly activates the precursors of IL-1β and IL-18 [44], leading to the maturation and release of IL-1β and IL-18.

The NLRP3 inflammasome plays an important role in ALI/ARDS. Studies have found that regulating the activation of NLRP3 can affect the process of ALI/ARDS. For
example, morin, a flavonoid that exhibits significant antioxidant and anti-inflammatory activity, can inhibit the activation of NLRP3 inflammasomes and further prevent LPS-induced ALI [45]. Melatonin directly inhibits the activation of NLRP3 inflammasomes and improves ALI/ARDS by reducing the release of extracellular histones [46]. Additionally, pirfenidone can improve LPS-induced lung inflammation by blocking the activation of NLRP3 inflammasomes and subsequent secretion of IL-1β [47]. These results indicate that these agents could be used as potential therapeutics.

2.2.4. PI3K/AKT Signaling Pathway

Recent studies have found that the PI3K/AKT signaling pathway is involved in the entire course of ALI/ARDS, including its etiology and pathogenesis. It is involved in early inflammation, pulmonary edema, and later tissue repair, airway remodeling, and emphysema [48]. On one hand, studies have shown that the phosphorylation levels of PI3K, AKT and mTOR were increased in LPS-induced ALI. Capsaicin (cap) is protective against LPS-induced ALI, which may be attributed to cap-mediated reduction of proinflammatory cytokines through inhibition of HMGB1/NF-κB and PI3K/AKT/mTOR pathways [49]. The activation of PI3K/AKT signaling pathway is consistent with the previous finding that cap induces autophagy and apoptosis in human nasopharyngeal carcinoma cells by downregulating the PI3K/AKT/mTOR pathway [50]. Similarly, studies have demonstrated that dexamethasone has a protective effect on LPS-induced ALI in vitro and in vivo, possibly by inhibiting inflammatory responses through HMGB1-mediated TLR4/NF-κB and PI3K/AKT/mTOR pathways [51]. The PI3K/AKT/mTOR and TLR4/NF-κB signaling pathways coordinate with each other in the inflammatory response [52], and NF-κB is a downstream target of AKT that activates NF-κB, leading to the translocation of p65 to the nucleus and the expression of proinflammatory genes [53]. On the other hand, Qu et al. found that the expression of PI3K/AKT signaling pathway was downregulated in LPS-induced ALI in vitro and in vivo experiments. Further studies found that glycyrrhizin acid induced autophagy by inhibiting the activation of the PI3K/AKT/mTOR pathway, thereby improving LPS-induced ALI [54]. Deng et al. [55] also reported that the PI3K/AKT signaling pathway was downregulated in an LPS-induced ALI rat model; however, they found that PI3K/AKT signaling pathway activation can enhance the activity of alveolar sodium channels and Na⁺-K⁺-ATP, thereby removing the excess edema fluid and reducing the exudation of protein-rich fluid in the alveoli, which ultimately reduces lung tissue damage [56]. Another study also showed that insulin could reduce LPS-induced pulmonary edema in ALI rats, enhance alveolar fluid clearance and alleviate lung injury by activating PI3K/AKT signaling pathway, inhibiting Nedd4-2, and increasing ENaC expression [57]. However, these differences also suggest that the activation or inhibition of the PI3K/AKT pathway may be related to the time point selected by the injury model. The activation of the PI3K/AKT pathway may occur in the early stage, and the PI3K/AKT pathway may have a synergistic relationship with different pathways, especially the NF-κB signaling pathway.

2.2.5. p38 MAPK Signaling Pathway

IL-1β, TNF-α, and other cytokines are chiefly produced in ALI/ARDS via the p38 MAPK signaling pathway [58]. Therefore, blocking the p38 MAPK signaling pathway can reduce the inflammatory response to some degree. For example, blocking the p38 MAPK signaling pathway with the p38 MAPK inhibitor SB203580 reduces excessive lung inflammation by inhibiting cell death caused by inflammatory macrophage apoptosis [58]. Epicatechin (EC), one of several anti-inflammatory interventions recently described, is also involved in LPS-induced ALI in a mouse model. EC may directly bind to the active site of p38 and inhibit its catalytic activity, thereby inhibiting inflammatory damage by inhibiting activation of the p38 MAPK-AP-1 signaling pathway [59]. Additionally, taurine can reduce ALI/ARDS caused by sepsis by inhibiting the p38/MAPK signaling pathway as well as inflammation and oxidative stress [60]. Thus, the p38/MAPK signaling pathway is being investigated as a potential therapeutic target for ALI/ARDS.
3. The Role of MicroRNAs in LPS-Induced ALI/ARDS

MicroRNAs chiefly bind to the 3'-UTR of mRNA to degrade or suppress the expression of target mRNA (Figure 2), which play a role in the physiological and pathological functions of a variety of disease processes. As previously stated, miRNAs play an important role in inflammation, and inflammation is an important characteristic of ALI/ARDS, miRNAs were proposed as diagnostic indicators and therapeutic targets for ALI/ARDS [24]. Indeed, studies have shown that miRNAs regulate ALI/ARDS via different mechanisms (Figure 3).

Figure 2. Biogenesis and biological function of miRNAs. RNA Pol II: RNA polymerase II; DGCR8: DiGeorge syndrome critical region 8; pri-miRNAs: primary miRNA; pre-miRNAs: microRNAs precursor; RISC: RNA-induced silencing complex; TRBP: TAR RNA binding proteins; AGO2: Argonaute 2; ORF: open reading frame.
3.1. Biogenesis and Biological Function of MiRNAs

Most miRNAs are initially transcribed by RNA polymerase II [61] in the nucleus into primary miRNA (pri-miRNA) with cap structure (7MGpppG) and polyadenylic acid tail (AAAAA) (Figure 2). In the classical pathway, the conversion of pri-miRNA into mature miRNA requires two steps, which are catalyzed by Drosha and Dicer, two members of the RNase III family. In the first step, these pri-miRNAs are processed into 60 to 100 nt RNAs with a stem-loop structure by the RNase III endonuclease Drosha as well as its cofactor DiGeorge syndrome critical region 8 (DGCR8) in the nucleus [62,63], termed pre-miRNAs. A single pri-miRNA can produce one or more pre-miRNAs. After pre-miRNAs are transported into the cytoplasm via Exportin-5, the second phase of miRNA biosynthesis [64] is initiated in the cytoplasm. In the cytoplasm, pre-miRNAs are cut by the second RNase III endonuclease Dicer, producing a mature miRNA duplex (miRNA-miRNA*) [65,66]. Subsequently, the miRNA duplex is loaded into the Argonaute (AGO) protein, together with Dicer and TAR RNA binding protein (TRBP), a known chaperone of the miRNA processing enzyme Dicer that alters the rate of pre-miRNA cleavage in an RNA structure-specific manner [67], to form the RNA-induced silencing complex (RISC). The miRNA strand in the miRNA complex is retained in RISC, whereas the miRNA* strand is degraded. Then, the RISC binds to the 3′ or 5′ UTR, open reading frame (ORF), or promoter region of the target mRNA [68]. As a key regulator of human miRNA processing and targeting, TRBP is required for the recruitment of AGO2 to Dicer-bound small interfering RNA (siRNA) [66].
Furthermore, TRBP can trigger the production of iso-miRNAs (isomiRs) that are one nucleotide longer than the standard sequence. It has been found that alterations in miRNA processing sites can alter guide strand selection, resulting in preferential silencing of different mRNA targets [67]. As the catalytic engine of RISC, AGO proteins, especially AGO2, mediate the process of miRNA-induced gene silencing, including miRNA degradation and translation inhibition [69]. For example, miR-223, a miRNA that is located on the X chromosome, is deregulated in various pathogenic conditions, such as type II diabetes, ALI, rheumatoid arthritis, and inflammatory bowel disease [70,71]. miR-223 specifically targets the 3′-UTR of NLRP3 mRNA, thereby inhibiting the translational expression of NLRP3 [72]. Therefore, NLRP3 expression can be controlled by regulating the expression of miR-223. In addition, miRNAs also regulate transcription factors through methylation, thus indirectly altering gene expression. For example, methylation of the miR-495 promoter region can downregulate its expression, contributing to the activation of the NLRP3 inflammasome and ultimately resulting in ALI/ARDS [73].

To date, greater than 2000 miRNA genes have been identified in the human genome [74]. Of note, each miRNA can target hundreds of mRNAs, and a single mRNA can be targeted by multiple miRNAs [75,76]. In addition, the expression of miRNAs has characteristics of tissue and cell specificity and time and space specificity, and miRNAs can represent useful clinical biomarkers [77]. For instance, miR-122, which is highly specifically expressed in the liver, is considered a promising biomarker of liver damage [78]. Additionally, miR-199b-3p, miR-1975, miR-15b, and miR-421 are considered to be biomarkers for liver cancer diagnosis [79], and miR-7, miR-9-5p, miR-9-3p, miR-129, and miR-132 [80] can be used as noninvasive methods to diagnose Parkinson’s disease. Zhu et al. [81] found that miR-652-3p can directly regulate KCNN3 to promote the proliferation, migration, and invasion of bladder cancer cells, and it is likely to be a potential target for bladder cancer treatment. In addition, some miRNAs, such as miR-150, miR-122, and miR-25, have been confirmed to be abnormally expressed in patients with sepsis and may be used as biomarkers for the early diagnosis and prognosis of sepsis [79]. These studies have laid a foundation for miRNA as a biomarker of ALI/ARDS.

3.2. Adverse Inflammation-Related MiRNAs

Some miRNAs can regulate ALI/ARDS by activating inflammatory responses. Inflammation-related miRNAs, such as miR-34a, miR-132, miR-155, miR-15a, miR-21, miR-27b, and miR-146a, were differentially expressed in lung tissues in an LPS-induced ALI model [82,83]. These miRNAs may regulate ALI/ARDS by activating inflammatory responses.

For example, miR-34a regulates alveolar epithelial cell function by targeting Forkhead box O3 (FOXO3) (Table 1) [84] or Angiotension 1 (Ang1) [85] to mediate the NF-κB signaling pathway [86]. The difference is that miR-326 and miR-300 also stimulate the NF-κB signaling pathway. The difference is that miR-326 targets B-cell lymphoma 2-related A1 (BCL2A1) [87] in the LPS-induced AEC model, and miR-300 targets the inhibitor kBα (IkBα) protein in A549 cells treated with LPS [88]. In a model of ALI induced by staphylococcal enterotoxin B (SEB), Rao et al. [89] found that miR-132 was upregulated, resulting in the inhibition of FOXO3 and the activation of NF-κB signaling pathway [90], which subsequently leads to an overactivation of the immune response, exacerbating inflammatory damage.

MiR-155, the main regulator of lymphocyte development, differentiation, and function, is initiated in macrophages/monocytes via the TLR2, TLR3, TLR4, or TLR9 signaling pathway and negatively regulates inflammatory responses by targeting MyD88, TAB2, IKKε, and/or other TLR signaling pathway components [91,92]. MiR-155 derived from serum exosomes can promote inflammation in ALI/ARDS by targeting suppressor of cytokine signaling 1 (SOCS1) [93], a known target of miR-155 that can inhibit NF-κB activity by reducing the stability of p65. Additionally, miR-155 can promote macrophage proliferation by targeting SHIP1, a tumor suppressor that can promote macrophage proliferation [93]. In addition, miR-155 also showed the ability to inhibit the M2 special factor C/EBPb and IL-13R, thereby inhibiting the development of alternately activated macrophages. This finding
indicates that miR-155 mutually exclusively regulates M1/M2 polarization [94]. Because M2 macrophages are mediated by the secretion of IL-10 and induce the expansion of CD4+ CD25+ regulatory T cells (Tregs), miR-155 antisense oligonucleotide (ASO) treatment can promote the recovery of ALI [95].

Goodwin et al. [96] found that miR-887-3p alters endothelial cell function in several important ways, including increased cytokine and neutrophil chemokine release and enhanced trans-endothelial migration, exacerbating the development of ARDS immune inflammation. In addition, studies have pointed out that inhibiting the expression of miR-34a-5p or miR-1246 can inhibit oxidative stress, reduce endothelial cell apoptosis, and reduce the expression level of inflammatory cytokines [86]. Furthermore, inhibiting the expression of miR-92a, miR-34b-5p, and miR-199a can reduce excessive inflammation and apoptosis while increasing the survival rate of ALI/ARDS mice [86]. In LPS-induced ALI mice, miR-203 can suppress the PI3K/AKT signaling pathway by inhibiting PIK3CA, a gene encoding a PI3K catalyst, to increase the downstream apoptotic proteins, and ultimately inhibit epithelial cell proliferation and promote apoptosis [97,98]. Furthermore, repressed miR-203 effectively attenuated LPS-induced interstitial pneumonia.

3.3. Protective Inflammation-Associated MiRNAs

3.3.1. Targeting ALI/ARDS through NF-κB Signaling Pathway

For the past few years, a series of studies have demonstrated that miRNAs can influence the pathological process of ALI/ARDS via TLR4/NF-κB signaling pathway. TLR4 expression is increased under LPS stimulation and could be inhibited by some miRNAs, which ultimately alter the inflammatory response. For example, miR-27a [99–101] and miR-16 [102] can inhibit the expression of TLR4 by targeting its 3′-UTR, reducing proinflammatory cytokine release and inflammatory responses by inhibiting downstream TLR4/MyD88/NF-κB signaling pathways [100]. Therefore, upregulating the expression of miR-27a and miR-16 is beneficial to suppress the inflammatory response. Similarly, in the LPS-induced ALI model, Yang et al. [103] found that miR-182 inhibits the activation of NF-κB by targeting the expression of TLR4, negatively regulates the TLR4/NF-κB pathway, and improves LPS-induced ALI. Furthermore, overexpression of miR-145-5p, miR-140, and miR-140-5p can inhibit TLR4 expression and block NF-κB pathway activation, thereby alleviating ALI/ARDS [86]. Additionally, miR-146a participates in TLR4/NF-κB signal transduction by inhibiting IRAK1 and TRAF6 [104], thus reducing proinflammatory factors, such as TNF-α, IL-6, and IL-1β, in alveolar macrophages. He et al. [105] found that miR-146b reduces lung inflammation and increases lung permeability by targeting IRAK1 to inhibit NF-κB signaling. Therefore, miR-146b overexpression could alleviate LPS-induced ALI. In the LPS-induced mouse ARDS model, miR-124-3p targets p65, promotes macrophage apoptosis, and plays a protective role in ARDS [106]. Sun et al. [107] suggested that miR-181b inhibits the NF-κB signaling pathway mainly by directly targeting importin-α3, a key protein in nuclear translocation of NF-κB. In contrast, miR-181b was detected to be elevated after LPS treatment of Beas-2b cells for 48 h [108]. Overexpressed miR-181b increases p65 and activates the NF-κB signaling pathway [109]. The changes and roles of miR-181b in lung injury need further experimental verification.

3.3.2. Targeting ALI/ARDS through JAK2/STAT3 Signaling Pathway

MiRNAs can affect the pathological process of ALI/ARDS through the JAK2/STAT3 signaling pathway, and JAK2/STAT3 inhibitor intervention can reverse the proinflammatory response induced by ALI/ARDS. Studies have confirmed that miR-21 expression is inhibited and JAK2/STAT3 and NF-κB signal transduction is activated in LPS-induced ALI/ARDS [110]. Upregulation of miR-21 can inhibit the JAK2/STAT3 signaling pathway, thereby reducing the infiltration of inflammatory cells in the lung tissue of ALI/ARDS mice induced by LPS [110]. Similarly, Kong et al. [111] noted that miR-216a expression was sharply reduced in ALI/ARDS patients and overexpression of miR-216a can inhibit the JAK2/STAT3 signaling pathway, inhibiting cell apoptosis, autophagy, and the release of in-
flammatory factors [111], thereby reducing LPS-induced ALI/ARDS. In addition, miR-30b-5p can bind to the 3'-UTR of suppressor of cytokine signaling 3 (SOCS3) [112], negatively regulating the JAK2/STAT3 pathway that mediates inflammation of lung macrophages and inhibiting the expression of ALI/ARDS inflammatory factors [113]. In addition, in a lung injury model in vivo, miR-127 was found to be downregulated, and its overexpression weakened lung permeability, inflammatory cell infiltration, cytokines, complement components, and STAT3 activation and signal transduction [114]. Further research found that miR-127 suppresses lung inflammation by targeting macrophage CD64 [114]. In contrast to this study, studies have shown that miR-127 targets B-cell lymphoma 6 (BCL6), which subsequently reduces the expression of dual-specific phosphatase 1 (DUSP1), and the JNK kinase and P38 MAPK signaling pathways are subsequently activated. This ultimately results in the formation of proinflammatory macrophages and a significant increase in proinflammatory cytokines [94]. However, these differences also demonstrate that miRNAs and diseases are related to time, cells, and damage models.

3.3.3. Targeting ALI/ARDS by Regulating NLRP3 Signaling Pathway

NLRP3 is linked to the occurrence and progression of pulmonary inflammatory diseases [115]. Overexpression of miR-495 inhibits the development of ALI/ARDS by negatively regulating NLRP3. This finding indicates that miR-495 upregulation could serve as a promising therapeutic target for ALI/ARDS treatment [73]. Additionally, You et al. [116] confirmed that miR-802 can improve lung injury induced by LPS by targeting pellino E3 ubiquitin-protein ligase family member 2 (Peli2), which mediates the activation of NLRP3 by promoting its ubiquitination [117]. Evidence indicates that the activation of NLRP3 inflammasome can be inhibited by miR-223 [73,118], which consequently reduces inflammation and improves ALI/ARDS.

3.3.4. Targeting ALI/ARDS through PI3K/AKT Signaling Pathway

Previous research has shown that the PI3K/AKT signaling pathway is significant in the regulation of ALI/ARDS by miRNAs. For example, miR-92a expression is increased in the HPMEC model induced by LPS [119]. Inhibition of miR-92a expression can significantly increase the migration of HPMECs, enhance the formation of blood vessels, and improve endothelial cell barrier dysfunction [119]. A further study found that miR-92 can target integrin α5 (ITGA5), thereby inhibiting the PI3K/AKT signaling pathway. Therefore, miR-92a inhibitors can act as protective agents for alveolar vascular endothelial cells [100]. Zhou et al. [120] found in the LPS-induced mouse ARDS model that miR-21a-3p in stromal cell Telocytes (TCs) could regulate the PI3K (p110α)/Akt/mTOR pathway to promote lung tissue repair and angiogenesis, which is beneficial to recovery of ARDS.

Table 1. Targets and function of microRNA in ALI/ARDS.

| Type    | MicroRNA | Damage Factors | Target         | Expression | Function       | Signaling Pathway          | Reference |
|---------|----------|----------------|----------------|------------|----------------|---------------------------|-----------|
| Adverse | miR-34a  | LPS            | FOXO3          | upregulation | Proinflammatory | NF-κB signaling pathway  | [84]      |
|         | miR-34a  | Hypoxia        | Ang1           | upregulation | Proinflammatory | NF-κB signaling pathway  | [85]      |
|         | miR-326  | LPS            | BCL2A1         | upregulation | Proinflammatory | NF-κB signaling pathway  | [87]      |
|         | miR-300  | LPS            | 1αx3βx         | upregulation | Proinflammatory | NF-κB signaling pathway  | [88]      |
|         | miR-132  | SEB            | FOXO3          | upregulation | Proinflammatory | NF-κB signaling pathway  | [89]      |
Table 1. Cont.

| Type | MicroRNA | Damage Factors | Target | Expression | Function  | Signaling Pathway | Reference |
|------|----------|----------------|--------|------------|-----------|-------------------|-----------|
|      | miR-155  | LPS            | SOCS1  | upregulation | Proinflammatory | NF-κB signaling pathway | [93]       |
|      | miR-155  | LPS            | C/EBPb and IL-13R | upregulation | Proinflammatory | regulates M1/M2 polarization | [94]       |
|      | miR-887-3p | LPS         |         | upregulation | Proinflammatory |                     | [96]       |
|      | miR-34a-5p | LPS and hypoxia | SIRT1  | upregulation | Proinflammatory |                     | [121]      |
|      | miR-124-5p | LPS          | ACE2   | upregulation | Proinflammatory |                     | [122]      |
|      | miR-92a   | LPS            | ITGA5   | upregulation | Proinflammatory | PI3K/AKT signaling pathway | [119]      |
|      | miR-34b-5p | LPS          | PGRN   | upregulation | Proinflammatory |                     | [123]      |
|      | miR-199a  | LPS            | SIRT1   | upregulation | Proinflammatory |                     | [124]      |
|      | miR-181b  | LPS            | P65     | upregulation | Proinflammatory | NF-κB signaling pathway | [108,109] |
|      | miR-127   | LPS            | BCL6    | upregulation | Proinflammatory | F38 MAPK signaling pathway | [94]       |
|      | miR-27a   | LPS            | TLR4    | downregulation | anti-inflammatory | NF-κB signaling pathway | [99,100]  |
|      | miR-16    | LPS            | TLR4    | downregulation | anti-inflammatory | NF-κB signaling pathway | [102]      |
|      | miR-182   | LPS            | TLR4    | downregulation | anti-inflammatory | NF-κB signaling pathway | [103]      |
|      | miR-145-5p | LPS          | TLR4    | downregulation | anti-inflammatory | NF-κB signaling pathway | [125]      |
|      | miR-140   | LPS            | TLR4    | downregulation | anti-inflammatory | NF-κB signaling pathway | [126]      |
|      | miR-140-5p | LPS          | TLR4    | downregulation | anti-inflammatory | NF-κB signaling pathway | [127]      |
|      | miR-146a  | LPS            | IRAK1   | Traf6       | downregulation | anti-inflammatory | NF-κB signaling pathway | [104]      |
|      | miR-146b  | LPS            | IRAK1   | downregulation | anti-inflammatory | NF-κB signaling pathway | [105]      |
|      | miR-181b  | LPS            | importin-α3 | downregulation | anti-inflammatory | NF-κB signaling pathway | [107]      |
|      | miR-124-3p | LPS          | p65     | downregulation | anti-inflammatory | NF-κB signaling pathway | [106]      |
|      | miR-21    | LPS            | JAK2    | downregulation | anti-inflammatory | JAK2/STAT3 and NF-κB signaling pathways | [110] |
|      | miR-21a   | LPS            | JAK2    | downregulation | anti-inflammatory | JAK2/STAT3 signal pathway | [111]      |
|      | miR-30b-5p | LPS          | SOCS3   | downregulation | anti-inflammatory | JAK2/STAT3 signal pathway | [112]      |
|      | miR-127   | LPS            | CD64    | downregulation | anti-inflammatory | STAT3 signaling pathway | [114]      |
|      | miR-495   | LPS            | NLRP3   | downregulation | anti-inflammatory | NLRP3 signaling pathway | [73]       |
|      | miR-802   | LPS            | Peli2   | downregulation | anti-inflammatory | NLRP3 signaling pathway | [117]      |
|      | miR-223   | LPS            | NLRP3   | downregulation | anti-inflammatory | NLRP3 signaling pathway | [73,118]  |
|      | miR-21a-3p | LPS          |         | downregulation | anti-inflammatory | PEAK (p110α)/Akt/mTOR pathway | [120] |

FoxO3: Forkhead box O3; Ang1: Angiotension 1; BCL2A1: B-cell lymphoma 2-related A1; IκBα: inhibitor of κBα; SOCS1: suppressor of cytokine signaling 1; SIRT1: Siruin 1; ACE2: Angiotensin-converting enzyme 2; ITGA5: integrin α5; SOCS3: suppressor of cytokine signaling 3; IRAK1: IL-1 receptor-associated kinase; TRAF6: Tumor necrosis factor receptor-associated factor; JAK2: Janus kinase 2; BCL6: B-cell lymphoma 6; Peli2: pellino E3 ubiquitin-protein ligase family member 2.

3.4. Acute Lung Injury/Acute Respiratory Distress Syndrome and Exosomal MicroRNAs

Exosomes, secreted microvesicles that transport miRNAs, mRNAs, and proteins via humoral transport, facilitate intercellular communication and initiate immune responses.
The content of exosomes varies with cellular origin and physiological conditions, and can provide insights into how cells and systems respond to physiological perturbations.

McDonald et al. [128] demonstrated that LPS-stimulated macrophage-secreted exosomes carried higher levels of three mouse homologous human miRNAs (miR-21-3p, miR-146a and miR-146b) with known roles in preventing overactivation of the innate immune response (Figure 4). This results in inhibition of transcription and translation of proinflammatory cytokines. Multiple studies have shown that exosomes transfected with miR-145 and miR-223/142 can target mouse alveolar macrophages, reduce the secretion of inflammatory cytokines IL-2 and TNF-α, and inhibit the activation of NLRP3 inflammasome. Thus, inflammation can be reduced and sepsis-ALI can be improved [16,129,130]. Related studies have also shown that MSC-derived exosomes carrying miR-30b-3p can inhibit the apoptosis of AEC in LPS mice by reducing the level of human serum amyloid A3, and play a protective role in the lung of ALI mice [130]. Conversely, in vitro and in vivo experiments have shown that miR-155 derived from macrophage exosomes mentioned above has a proinflammatory effect by activating the NF-κB signaling pathway to induce inflammatory responses [93].

![Image](https://example.com/image1.png)

**Figure 4.** The role of exosomal microRNAs in LPS-induced ALI/ARDS.

In addition, Quan et al. [131] found that exosomes derived from alveolar progenitor Type II cell (AT II C) multipotent stem cells carrying miR-371b-5p can improve the survival probability and even promote the proliferation of AT II C and promote the regeneration of damaged alveolar epithelium. Furthermore, endothelial progenitor cell-derived exosomes are enriched in miR-126, which can target and downregulate Sprouty-related EVH1 domain-containing protein 1 (SPRED1) and activate rapidly accelerated fibrosarcoma/extracellular signal regulated kinase (RAF/ERK) signaling pathway, improve endothelial cell function, enhance endothelial cell proliferation, migration, and tubule formation, and improve LPS-induced ALI and restoring lung integrity in vivo [132,133]. Furthermore, in ALI, the release of various proinflammatory factors by M0-Exosome vesicles (EVs) in bronchoalveolar lavage fluid is mainly damaged in the early stages. This activates neutrophils to produce IL-10, which may be responsible for polarizing M0 to M2c, leading to fibrosis after ALI [134].

In conclusion, exosomes possess systemic signaling capabilities, induce pleiotropic effects, and have great therapeutic potential.
4. The Potential Role of MiRNAs in Clinical Treatment of ALI/ARDS

Since the discovery of miRNAs in 1993, the field has progressed rapidly, and great achievements have been made in various aspects. Insights into the role of miRNAs in development and disease have also made miRNAs attractive tools and targets for novel therapeutic approaches.

In cancer diseases, for example, miRNAs function as tumor suppressor-miRs or onco-genes (OncomiRs), and miRNA mimics and miRNA-targeting molecules (anti-miRs) have shown promise in preclinical development [135]. In view of the many-to-many relationship between miRNAs and target genes, the targets selected in current clinical trials are generally proven to target multiple oncogenes or tumor suppressor genes [136], and miRNAs that function as Onco-miRs or Suppressor-miRs in a variety of malignant tumors [137]. Several miRNA-targeted therapies are already in clinical development. For example, Zhang et al. [138] found that the combination of six miRNAs (miR-21-5p, miR-20a-5p, miR-103a-3p, miR-106b-5p, miR-143-5p and miR-215) in tissues could be used to predict the effect of new treatment and long-term prognosis of stage II colon cancer patients. Wiemer et al. [139] conducted a clinical trial (NCT00413192) (Table 2) and found that 26 miRNAs could be used to predict the efficacy of the microtubule dynamics inhibitor eribulin in the treatment of metastatic soft tissue sarcoma. Miravirsen, which is also known as SPC3649, is an antagonist of miR-122 [78]. It is the world’s first microRNA drug tested in humans as a new treatment for hepatitis C. Upon hepatitis C virus infection, the level of miR-122 is elevated. Unlike typical miRNAs, miR-122 activates mRNA, thereby enhancing the expression of hepatitis C-related genes and aggravating infection. Therefore, inhibiting the activity of miR-122 can play a therapeutic role. At present, Miravirsen has passed Phase IV clinical trials [140], demonstrating that it is safe in the human body and indeed reduces the expression level of the hepatitis C virus. Other miRNA drugs for tumors such as antagonists of miR-34, let-7, and miR-16 are still in progress. Regarding the development of miRNA mimic-based cancer therapy, the most advanced compound is MRX34, a miR-34 mimic encapsulated in a lipid carrier called NOV40 [141], which has reached Phase I clinical trials for the treatment of cancer [141,142]. In mice treated with MRX34 nanoparticles, accumulation of miR-34 in tumors was observed, as well as significant tumor regression [141,143–145].

There are relatively few clinical trials targeting Onco-miRs, including one on the cancer-promoting molecule miR-155 (NCT025580552), in which researchers designed and synthesized a locked nucleic acid (LNA) called Cobomarset or MRG-106 for the treatment of cutaneous T-lymphoma, Alibell’s disease, chronic lymphocytic leukemia and adult T-cell leukemia and lymphoma. The test has now been completed [146].

The application of miRNAs has also been studied in other diseases, such as cardiovascular disease. In an African green monkey model highly related to humans, antisense oligonucleotide inhibition of miR-33a/b was found to be a promising therapeutic strategy. It increases plasma high-density lipoprotein (HDL) and decreases very low-density lipoprotein (VLDL)-related triglyceride levels, used to treat dyslipidemia that increases the risk of cardiovascular disease, such as atherosclerosis [147]. Similarly, anti-miR-144 may also be a new approach to target HDL and reverse cholesterol transport [148]. Currently, the application of miRNAs in cardiac diseases is mostly focused on the biomarkers of disease occurrence and progression [149]. With further research, the first miR-132 inhibitor (CDR132L) for heart failure has entered clinical trials [149]. The success of this clinical trial marks the official entry of miRNA in the treatment of heart disease, setting a precedent for other miRNAs entering the clinic in the future for the treatment of heart disease [149]. In addition, studies have shown that miR-195-5p promotes cardiac hypertrophy by targeting MFN2 and FBXW7, which may provide a promising therapeutic strategy for intervening cardiac hypertrophy [150].
At present, clinical trials using miRNAs as therapeutic targets focus on tumors, such as lung cancer, liver cancer and other diseases, and there are almost no clinical trials of miRNA for the diagnosis or treatment of ALI/ARDS. In the Clinical Trial website, a clinical experiment named “The Role of Circulating CircRNAs and MicroRNAs in Acute Lung Injury” (NCT03766204) is being carried out by Changhai hospital. The trial is currently recruiting and is expected to screen several non-coding RNAs as new biomarkers for ALI/ARDS. Therefore, clinical trials of miRNAs as therapeutic targets in ALI/ARDS are urgently needed, and the clinical application of miRNAs in ALI/ARDS deserves attention. As miRNAs play important roles in the process of ALI/ARDS, they have great prospects in the clinical treatment of ALI/ARDS. With the proliferation of human genome data and the development of new delivery vectors, we are optimistic that the use of miRNAs as therapeutic targets for ALI/ARDS will become a clinical reality.

Table 2. MicroRNAs in clinical trials.

| Name (Company) | Therapeutic Agent | Target Diseases | Trial Details | Clinical Trials.Gov Identifier | Reference |
|----------------|-------------------|-----------------|---------------|-------------------------------|-----------|
| Mirvirasen (Santaris Pharma A/S and Hoffmann-La Roche) | Anti-miR-122 | Hepatitis C (chronic infections included) | Phase III, completed | NCT01728324 | [78,135] |
| Mirvirasen (Santaris Pharma A/S and Hoffmann-La Roche) | Anti-miR-122 | Hepatitis C (chronic infections included) | Phase III, completed | NCT01366638 | |
| Mirvirasen (Santaris Pharma A/S and Hoffmann-La Roche) | Anti-miR-122 | Hepatitis C (chronic infections included) | Phase IV, completed | NCT01222611 | |
| Mirvirasen (Santaris Pharma A/S and Hoffmann-La Roche) | Anti-miR-122 | Hepatitis C (chronic infections included) | Phase II, completed | NCT00996476 | |
| Mirvirasen (Santaris Pharma A/S and Hoffmann-La Roche) | Anti-miR-122 | Hepatitis C (chronic infections included) | Phase III, completed | NCT01725529 | |
| Mirvirasen (Santaris Pharma A/S and Hoffmann-La Roche) | Anti-miR-122 | Hepatitis C (chronic infections included) | Phase III, completed | NCT01290731 | |
| Mirvirasen (Santaris Pharma A/S and Hoffmann-La Roche) | Anti-miR-122 | Hepatitis C (chronic infections included) | Phase III, completed | NCT01292239 | |
| Mirvirasen (Santaris Pharma A/S and Hoffmann-La Roche) | Anti-miR-122 | Hepatitis C (chronic infections included) | Phase III, completed | NCT01288209 | |
| Cobomarsen or MRG-106 (miRagen Therapeutics) | Anti-miR-155 | cutaneous T-lymphoma, Alibell’s disease, chronic lymphocytic leukemia and adult T-cell leukemia and lymphoma | Phase I, completed | NCT02580552 | [146] |
| CDR132L | miR-132 inhibitor | heart disease | Phase I, completed | NCT04045405 | [149] |
| MRX34 (Mirna Therapeutics) | miR-34 mimic | multiple solid tumours | Multicentre phase I, terminated | NCT01829971 | [141–145] |
| MesomiR-1 (EnGeneIC) | miR-16 mimic | mesothelioma, non-small cell lung cancer | Phase I, completed | NCT02369198 | [135] |
| Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | miR-132 mimic | heart disease | Phase I, completed | NCT04045405 | |
| Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | miR-34 mimic | multiple solid tumours | Multicentre phase I, terminated | NCT01829971 | |
| Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS) | miR-16 mimic | mesothelioma, non-small cell lung cancer | Phase I, completed | NCT02369198 | |

At present, clinical trials using miRNAs as therapeutic targets focus on tumors, such as lung cancer, liver cancer and other diseases, and there are almost no clinical trials of miRNA for the diagnosis or treatment of ALI/ARDS. In the Clinical Trial website, a clinical experiment named “The Role of Circulating CircRNAs and MicroRNAs in Acute Lung Injury” (NCT03766204) is being carried out by Changhai hospital. The trial is currently recruiting and is expected to screen several non-coding RNAs as new biomarkers for ALI/ARDS. Therefore, clinical trials of miRNAs as therapeutic targets in ALI/ARDS are urgently needed, and the clinical application of miRNAs in ALI/ARDS deserves attention. As miRNAs play important roles in the process of ALI/ARDS, they have great prospects in the clinical treatment of ALI/ARDS. With the proliferation of human genome data and the development of new delivery vectors, we are optimistic that the use of miRNAs as therapeutic targets for ALI/ARDS will become a clinical reality.
5. Summary and Future Prospects

Due to the complex etiology of ALI/ARDS, after half a century, although significant progress has been made in the pathogenesis of ALI/ARDS, the exact pathogenesis of ALI/ARDS has not yet been fully elucidated. At present, uncontrolled inflammation is generally believed to be the main pathophysiological change in ALI/ARDS [58,101,151]. Therefore, inhibiting the uncontrolled inflammatory response may be the key strategy for ALI/ARDS treatment. Evidence indicates that miRNAs play an essential role in regulating the inflammatory response process in ALI/ARDS. Therefore, exploring the miRNAs related to inflammatory signaling pathways in ALI/ARDS has very important clinical significance for the early diagnosis and treatment of diseases. This article describes the role of miRNAs in the pathogenesis of ALI/ARDS from miRNA-related inflammatory signaling pathways to provide new treatment ideas for ALI/ARDS.

Although research on the regulation of ALI/ARDS by miRNAs is still constantly being updated, the existing research conclusions are sufficient to demonstrate its importance in the occurrence and progression of ALI/ARDS. These regulatory effects exist at the level of cells, receptors, signaling pathways, and gene transcription [152]. Such a complex and delicate regulatory mechanism of miRNA makes the entire signaling pathway a promising therapeutic drug (usually in the form of miRNA analogs) or drug therapy targets (usually in the form of anti-miRNA) in several pathological processes.

Increasing evidence shows that changes in specific miRNA levels are correlated with various diseases, and miRNAs are considered as potential biomarkers for the diagnosis of various diseases, such as cancer and cardiovascular diseases. As mentioned above, miRNAs play an essential role in regulating the inflammatory response, the expression of miRNAs (such as miR-155, miR-27a, miR-21, miR-146a, and miR-223) is altered in ALI/ARDS, and some miRNAs have also been shown to be new biomarkers for the prognosis of ALI/ARDS. Consequently, miRNAs are also considered as potential therapeutic targets for diseases, and clinical trials of some miRNA drugs are underway.

In summary, this article describes the function of miRNAs in the pathogenesis of ALI/ARDS, and increasing the expression of protective miRNAs and inhibiting unfavorable miRNAs have been demonstrated to be effective in alleviating ALI/ARDS in many studies. Some miRNAs have also been shown to be biomarkers of ALI/ARDS; therefore, regulating the expression of miRNAs in ALI/ARDS may represent a future treatment direction for lung injury.

Author Contributions: Investigation, Q.L., S.Y., J.L., M.S., S.H., J.Z., Y.L. and M.J.; Writing—original draft preparation, S.Y.; Writing—review and editing, Q.L.; Visualization: S.Y. and Q.L.; Supervision, Y.Z. and H.F.; Project administration, X.M.; Funding acquisition, H.F. and Y.Z. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Open Scientific Research Program of Military Logistics by Haojun Fan (BLB19006) and Yanmei Zhao (BLB20009).

Institutional Review Board Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We gratefully acknowledge the co-workers of our team.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Mokra, D.; Kosutova, P. Biomarkers in acute lung injury. Respir. Physiol. Neurobiol. 2015, 209, 52–58. [CrossRef] [PubMed]
2. Hui, Y.; Yan, S.G.; Li, J.T.; Wei, H.L.; Shi, J. Research progress in the treatment of acute lung injury by vasoactive intestinal peptide regulating alveolar macrophage M1/M2 polarization. Chin. J. Immunol. 2021, 1–9. Available online: http://kns.cnki.net/kcms/detail/22.1126.R.20210625.1333.006.html (accessed on 10 April 2022).
3. Kumar, V. Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury. Front. Immunol. 2020, 11, 1722. [CrossRef] [PubMed]
Baradaran Rahimi, V.; Rakhshandeh, H.; Raucci, F.; Buono, B.; Shirazinia, R.; Samzadeh Kermani, A.; Maione, F.; Mascolo, N.; Askari, V.R. Anti-Inflammatory and Anti-Oxidant Activity of Portulaca oleracea Extract on LPS-Induced Rat Lung Injury. Molecules 2019, 24, 139. [CrossRef] [PubMed]

Wolf, S.J.; Bebarta, V.S.; Bonnett, C.J.; Fons, P.T.; Cantrill, S.V. Blast injuries. Lancet 2009, 374, 405–415. [CrossRef]

Zhang, Y.; Xie, Y.; Zhang, L.; Zhao, H. MicroRNA-155 Participates in Smoke-Inhalation-Induced Acute Lung Injury through Inhibition of Socs-1. Molecules 2020, 25, 1022. [CrossRef]

Lu, Q.; Huang, S.; Meng, X.; Zhang, J.; Yu, S.; Li, J.; Shi, M.; Fan, H.; Zhao, Y. Mechanism of Phosgene-Induced Acute Lung Injury and Treatment Strategy. Int. J. Mol. Sci. 2021, 22, 10933. [CrossRef]

Hagen, J.W.; Lai, E.C. microRNA control of cell-cell signaling during development and disease.

Smith, S.A.; Jann, O.C.; Haig, D.; Russell, G.C.; Werling, D.; Glass, E.J.; Emes, R.D. Adaptive evolution of Toll-like receptor 5 in domesticated mammals. BMC Evol. Biol. 2012, 12, 122. [CrossRef]

Yan, Y.R. MicroRNA-223 Attenuates Inflammation in Acute Lung Injury via the NLRP3 Inflammasome and TLR4/NF-kappaB signalling pathways in major organs of the mouse after intravenous injection of lipopolysaccharide. Pharm. Biol. 2019, 57, 555–563. [CrossRef]

Imai, Y.; Kuba, K.; Neely, G.G.; Yaghubian-Malhami, R.; Perkmann, T.; van Loo, G.; Ermolaeva, M.; Veldhuizen, R.; Leung, Y.H.; Wang, H.; et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008, 133, 235–249. [CrossRef]

Malik, A.; Kanneganti, T.D. Inflammasome activation and assembly at a glance. J. Cell Sci. 2017, 130, 3955–3963. [CrossRef]
32. Sayan, M.; Mossman, B.T. The NLRP3 inflammasome in pathogenic particle and fibre-associated lung inflammation and diseases. *Part. Fibre Toxicol.* 2016, 13, 51. [CrossRef] [PubMed]

33. Shen, H.; Wu, N.; Wang, Y.; Guo, F.; Chen, L.; Zhang, Z.; Jia, D.; Zhao, M. Myd88 gene knockout attenuates paraquat-induced acute lung injury. *Toxicol. Lett.* 2017, 269, 41–46. [CrossRef] [PubMed]

34. Cervantes, J.L. Myd88 in Mycobacterium tuberculosis infection. *Med. Microbiol. Immunol.* 2017, 206, 187–193. [CrossRef] [PubMed]

35. Hu, R.; Xu, H.; Jiang, H.; Zhang, Y.; Sun, Y. The role of TLR4 in the pathogenesis of indirect acute lung injury. *Front. Biosci.* 2013, 18, 1244–1255.

36. Li, T.T.; Ogino, S.; Qian, Z.R. Toll-like receptor signaling in colorectal cancer: Carcinogenesis to cancer therapy. *World J. Gastroenterol.* 2014, 20, 17699–17708. [CrossRef]

37. Chen, O.; Tang, Z.H.; Hu, J.T. The role of Toll-like receptor 4 in sepsis-induced acute lung injury. *Guangdong Med.* 2019, 40, 1048–1052.

38. Li, B.; Xi, P.; Wang, Z.; Han, X.; Xu, Y.; Zhang, Y.; Miao, J. PI3K/Akt/mTOR signaling pathway participates in Streptococcus uberis-induced inflammation in mammary epithelial cells in concert with the classical TLRs/NF-κB pathway. *Vet. Microbiol.* 2018, 227, 103–111. [CrossRef]

39. Diao, Y.R.; Ding, Q.; Shi, Y.Y. Advances in the role of pattern recognition receptors PRRs in the pathogenesis of acute lung injury/acute respiratory distress syndrome. *Chin. J. Immunol.* 2022, 38, 227–233.

40. Zhao, J.; Yu, H.; Lü, Y.; Gibson, S.A.; Yan, Z.; Xu, X.; Gaggar, A.; Li, P.K.; Li, C.; Wei, S.; et al. Protective effect of suppressing STAT3 activity in LPS-induced acute lung injury. *Am. J. Physiol. Lung Cell Mol. Physiol.* 2016, 311, L868–L880. [CrossRef]

41. Li, Q.; Ye, W.X.; Huang, Z.J.; Zhang, Q.; He, Y.F. Effect of IL-6-mediated STAT3 signaling pathway on myocardial apoptosis in mice with dilated cardiomyopathy. *Eur. Rev. Med. Pharmacol. Sci.* 2019, 23, 3042–3050.

42. Xu, S.; Pan, X.; Mao, L.; Pan, H.; Xu, W.; Hu, Y.; Yu, X.; Chen, Z.; Qian, S.; Ye, Y.; et al. Phospho-Tyr705 of STAT3 is a therapeutic target for sepsis through regulating inflammation and coagulation. *Cell Commun. Signal.* 2020, 18, 104. [CrossRef] [PubMed]

43. Broz, P.; Dixit, V.M. Inflammasomes: Mechanism of assembly, regulation and signalling. *Nat. Rev. Immunol.* 2016, 16, 407–420. [CrossRef] [PubMed]

44. Lamkanfi, M.; Dixit, V.M. Mechanisms and functions of inflammasomes. *Cell* 2014, 157, 1013–1022. [CrossRef] [PubMed]

45. Tianzhu, Z.; Shihai, Y.; Juan, D. The effects of morin on lipopolysaccharide-induced acute lung injury by suppressing the lung NLRP3 inflammasome. *Inflammation* 2014, 37, 1976–1983. [CrossRef]

46. Zhang, Y.; Li, X.; Grailer, J.J.; Wang, N.; Wang, M.; Yao, J.; Zhong, R.; Gao, G.F.; Ward, P.A.; Tan, D.X.; et al. Melatonin alleviates heart injury via regulating miR-1 and PI3K/AKT pathway. *Chem.-Biol. Interact.* 2020, 286, 103197. [CrossRef] [PubMed]

47. Li, Y.; Li, H.; Liu, S.; Pan, P.; Su, X.; Tan, H.; Wu, D.; Zhang, L.; Song, C.; Dai, M.; et al. Pirfenidone ameliorates acute lung injury through the HMGB1-mediated TLR4/NF-κB pathway. *Vet. Microbiol.* 2018, 236, 5291–5304. [CrossRef]

48. Cao, H.; Feng, Y.; Ning, Y.; Zhang, Z.; Li, W.; Li, Q. Edaravone protects rats and human pulmonary alveolar epithelial cells against hyperoxia injury: Heme oxygenase-1 and PI3K/Akt pathway may be involved. *Exp. Lung Res.* 2015, 41, 404–414. [CrossRef]

49. Chen, H.; Li, N.; Zhan, X.; Zheng, T.; Huang, X.; Chen, Q.; Song, Z.; Yang, F.; Nie, H.; Zhang, Y.; et al. Capsaicin Protects Against Lipopolysaccharide-Induced Acute Lung Injury Through the HMGB1/NF-κB and PI3K/AKT/mTOR Pathways. *J. Inflamm. Res.* 2021, 14, 5291–5304. [CrossRef]

50. Lin, Y.T.; Wang, H.C.; Hsu, Y.C.; Cho, C.L.; Yang, M.Y.; Chien, C.Y. Capsaicin Induces Autophagy and Apoptosis in Human Nasopharyngeal Carcinoma Cells by Downregulating the PI3K/AKT/mTOR Pathways. *Int. J. Mol. Sci.* 2017, 18, 1343. [CrossRef]

51. Meng, L.; Li, L.; Lu, S.; Li, K.; Su, Z.; Wang, Y.; Fan, X.; Li, X.; Zhao, G. The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways. *Mol. Immunol.* 2018, 99, 134–144. [CrossRef] [PubMed]

52. Hao, H.; Cheng, S.; Zhang, Z.; Li, W.; Li, Q. Edaravone protects rats and human pulmonary alveolar epithelial cells against hyperoxia injury: Heme oxygenase-1 and PI3K/Akt pathway may be involved. *Exp. Lung Res.* 2015, 41, 404–414. [CrossRef]

53. Chen, H.; Li, N.; Zhan, X.; Zheng, T.; Huang, X.; Chen, Q.; Song, Z.; Yang, F.; Nie, H.; Zhang, Y.; et al. Capsaicin Protects Against Lipopolysaccharide-Induced Acute Lung Injury Through the HMGB1/NF-κB and PI3K/AKT/mTOR Pathways. *J. Inflamm. Res.* 2021, 14, 5291–5304. [CrossRef] [PubMed]

54. Lin, Y.T.; Wang, H.C.; Hsu, Y.C.; Cho, C.L.; Yang, M.Y.; Chien, C.Y. Capsaicin Induces Autophagy and Apoptosis in Human Nasopharyngeal Carcinoma Cells by Downregulating the PI3K/AKT/mTOR Pathways. *Int. J. Mol. Sci.* 2017, 18, 1343. [CrossRef]

55. Meng, L.; Li, L.; Lu, S.; Li, K.; Su, Z.; Wang, Y.; Fan, X.; Li, X.; Zhao, G. The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways. *Mol. Immunol.* 2018, 99, 134–144. [CrossRef] [PubMed]

56. Hao, H.; Cheng, S.; Zhang, Z.; Li, W.; Li, Q. Edaravone protects rats and human pulmonary alveolar epithelial cells against hyperoxia injury: Heme oxygenase-1 and PI3K/Akt pathway may be involved. *Exp. Lung Res.* 2015, 41, 404–414. [CrossRef]

57. Deng, W.; Wang, D.X.; Deng, J.; Zhou, T. PI3K/Akt signaling pathway up-regulates the expression of sodium channels in alveolar epithelium of rats with acute lung injury. *Basic Med. Clin. Pract.* 2012, 32, 1004–1008.

58. Zhang, P.Y.; Chen, M. Research progress on the role of PI3K/AKT signaling pathway in the occurrence and development of acute lung injury. *Shandong Med.* 2016, 56, 99–101.

59. Deng, W.; Li, C.Y.; Tong, J.; Zhang, W.; Wang, D.X. Regulation of ENaC-mediated alveolar fluid clearance by insulin via PI3K/Akt pathway in LPS-induced acute lung injury. *Respir. Res.* 2012, 13, 29. [CrossRef]

60. Li, D.; Ren, W.; Jiang, Z.; Zhu, L. Regulation of the NLRP3 inflammasome and macrophage pyroptosis by the p38 MAPK signaling pathway in a mouse model of acute lung injury. *Mol. Med. Rep.* 2018, 18, 4399–4409. [CrossRef]
59. Xing, J.; Yu, Z.; Zhang, X.; Li, W.; Gao, D.; Wang, J.; Ma, X.; Nie, X.; Wang, W. Epicatechin alleviates inflammation in lipopolysaccharide-induced acute lung injury in mice by inhibiting the p38 MAPK signaling pathway. *Int. Immunopharmacol.* 2019, 66, 146–153. [CrossRef]

60. Jiao, C.; Xiang, X.; Jianqing, C.; Ling, J.; Baodi, S.; Wei, Z. Protective effect of taurine on sepsis-induced lung injury via inhibiting the p38/MAPK signaling pathway. *Med. Mol. Rep.* 2021, 24, 1–10.

61. Du, T.; Zamore, P.D. Beginning to understand microRNA function. *Cell Res.* 2007, 17, 661–663. [CrossRef]

62. Denli, A.M.; Tops, B.B.; Plasterik, R.H.; Ketting, R.F.; Hannon, G.J. Processing of primary microRNAs by the Microprocessor complex. *Nature* 2004, 432, 231–235. [CrossRef] [PubMed]

63. Han, J.; Lee, Y.; Yeom, K.H.; Kim, Y.K.; Jin, H.; Kim, V.N. The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev.* 2004, 18, 3016–3027. [CrossRef] [PubMed]

64. Con, Y.; Shimizu, T.; Mizumura, K.; Maruoka, S.; Hikichi, M. Molecular techniques for respiratory diseases: MicroRNA and extracellular vesicles. *Respiration* 2020, 25, 149–160. [CrossRef]

65. Murchison, E.P.; Hannon, G.J. miRNAs on the move: miRNA biogenesis and the RNAi machinery. *Curr. Opin. Cell Biol.* 2004, 16, 223–229. [CrossRef] [PubMed]

66. Chengrimada, T.P.; Gregory, R.I.; Kumaraswamy, E.; Norman, J.; Cooch, N.; Nishikura, K.; Shiekhattar, R. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. *Nature* 2005, 436, 740–744. [CrossRef]

67. Lee, H.Y.; Doudna, J.A. TRBP alters human precursor microRNA processing in vitro. *RNA* 2012, 18, 2012–2019. [CrossRef]

68. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. *Cell* 2009, 136, 215–223. [CrossRef]

69. Ye, Z.; Jin, H.; Qian, Q. Argonaute 2: A Novel Rising Star in Cancer Research. *J. Cancer* 2015, 6, 877–882. [CrossRef]

70. Yuan, X.; Berg, N.; Lee, J.W.; Le, T.T.; Neudecker, V.; Jing, N.; Eltzschig, H. MicroRNA miR-223 as regulator of innate immunity. *J. Leukoc. Biol.* 2018, 104, 515–524. [CrossRef]

71. Haneklaus, M.; Gerlic, M.; O’Neill, L.A.; Masters, S.L. miR-223: Infection, inflammation and cancer. *J. Intern. Med.* 2013, 274, 215–226. [CrossRef]

72. Liu, W.; Guo, W.J.; Xu, Q.; Sun, Q. Advances in mechanisms for NLRP3 inflammasomes regulation. *Acta Pharm. Sin.* 2016, 51, 1505–1512.

73. Ying, Y.; Mao, Y.; Yao, M. NLRP3 Inflammasome Activation by MicroRNA-495 Promoter Methylation May Contribute to the Progression of Acute Lung Injury. *Mol. Ther. Nucleic Acids* 2019, 18, 801–814. [CrossRef] [PubMed]

74. Moschos, S.A.; Williams, A.E.; Perry, M.M.; Birrell, M.A.; Belvisi, M.G.; Lindsay, M.A. Expression profiling in vivo demonstrates rapid changes in lung microRNA levels following lipopolysaccharide-induced inflammation but not in the anti-inflammatory action of glucocorticoids. *BMC Genom.* 2007, 8, 240. [CrossRef] [PubMed]

75. Bartel, D.P.; Chen, C.Z. Micromanagers of gene expression: The potentially widespread influence of metazoan microRNAs. *Nat. Rev. Genet.* 2004, 5, 396–400. [CrossRef] [PubMed]

76. Doench, J.G.; Sharp, P.A. Specificity of microRNA target selection in translational repression. *Genes Dev.* 2004, 18, 504–511. [CrossRef] [PubMed]

77. Staszew, T.; Zapala, B.; Polus, A.; Sadakierska-Chudy, A.; Kieć-Wilb, B.; Stepień, E.; Wybrańska, I.; Chojnacka, M.; Dembińska-Kieć, A. Role of microRNAs in endothelial cell pathophysiology. *Pol. Arch. Med. Wewn.* 2011, 121, 361–366. [CrossRef] [PubMed]

78. Bandiera, S.; Peffer, S.; Baumert, T.F.; Ziesler, M.B. miR-122–2–a key factor and therapeutic target in liver disease. *J. Hepatol.* 2015, 62, 448–457. [CrossRef]

79. Qin, X.M.; Ren, G.Q. Research progress of miRNA as biomarkers for sepsis and its complications. *Med. Recapitul.* 2021, 19, 3796–7801.

80. Alleva, A.; Filatova, E.V.; Karabanov, A.V.; Illarishkin, S.N.; Limborska, S.A.; Shadrina, M.I.; Slominsky, P.A. miRNA expression is highly sensitive to a drug therapy in Parkinson’s disease. *Parkinsonism Relat. Disord.* 2015, 21, 72–74. [CrossRef]

81. Zhu, Q.L.; Zhan, D.M.; Chong, Y.K.; Ding, L.; Yang, Y.G. MiR-652-3p promotes bladder cancer migration and invasion by targeting KCNN3. *Eur. Rev. Med. Pharmacol. Sci.* 2019, 23, 8806–8812.

82. Li, J.J.; Wang, B.; Kodal, M.C.; Chen, C.; Kim, E.; Patters, B.J.; Lan, L.; Kumar, S.; Wang, X.; Yue, J.; et al. In vivo evidence for the contribution of peripheral circulating inflammatory exosomes to neuroinflammation. *J. Neuroinflamm.* 2018, 15, 8. [CrossRef] [PubMed]

83. Poon, K.S.; Palanisamy, K.; Chang, S.S.; Sun, K.T.; Chen, K.B.; Li, P.C.; Lin, T.C.; Li, C.Y. Plasma exosomal miR-223 expression regulates inflammatory responses during cardiac surgery with cardiopulmonary bypass. *Sci. Rep.* 2017, 7, 10807. [CrossRef] [PubMed]

84. Song, L.; Zhou, F.; Cheng, L.; Hu, M.; He, Y.; Zhang, B.; Liao, D.; Xu, Z. MicroRNA-34a Suppresses Autophagy in Alveolar Type II Epithelial Cells in Acute Lung Injury by Inhibiting FoxO3 Expression. *Inflammation* 2017, 40, 927–936. [CrossRef] [PubMed]

85. Syed, M.; Das, P.; Pawar, A.; Aghai, Z.H.; Kaskinen, A.; Zhuang, Z.W.; Ambalavanan, N.; Pryhuber, G.; Andersson, S.; Bhandari, V. Hyperoxia causes miR-34a-mediated injury via angiopoietin-1 in neonatal lungs. *Nat. Commun.* 2017, 8, 1173. [CrossRef]

86. Jin, X.H.; Shi, X.; Lv, X. Research progress on roles of microRNA in acute lung injury. *J. Tongji Univ.* 2021, 42, 554–561.

87. Wu, C.T.; Huang, Y.; Pei, Z.Y.; Xi, X.; Zhu, G.F. MicroRNA-326 aggravates acute lung injury in septic shock by mediating the NF-κB signaling pathway. *Int. J. Biochem. Cell Biol.* 2018, 101, 1–11. [CrossRef]

88. Cao, W.; Dai, H.; Yang, S.; Liu, Z.; Yi Chen, Q. Increased serum miR-300 level serves as a potential biomarker of lipopolysaccharide-induced lung injury by targeting IκBα. *Die Pharm.* 2017, 72, 5–9.
91. O’Neill, L.A.; Sheedy, F.J.; McCoy, C.E. MicroRNAs: The fine-tuners of Toll-like receptor signalling. Nat. Rev. Immunol. 2011, 11, 163–175. [CrossRef]

92. O’Connell, R.M.; Taganov, K.D.; Boldin, M.P.; Cheng, G.; Baltimore, D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc. Natl. Acad. Sci. USA 2007, 104, 1604–1609. [PubMed]

93. Jiang, K.; Yang, J.; Guo, S.; Zhao, G.; Wu, H.; Deng, G. Peripheral Circulating Exosome-Mediated Delivery of miR-155 as a Novel Mechanism for Acute Lung Inflammation. Mol. Ther. J. Am. Soc. Gene Ther. 2019, 27, 1758–1771. [CrossRef]

94. Ying, H.; Kang, Y.; Zhang, H.; Zhao, D.; Xia, J.; Lu, Z.; Wang, H.; Xu, F.; Shi, L. MiR-127 modulates macrophage polarization and promotes lung inflammation and injury by activating the JNK pathway. J. Immunol. 2015, 194, 1239–1251. [CrossRef]

95. Guo, Z.; Wen, Z.; Qin, A.; Zhou, Y.; Liao, Z.; Liu, Z.; Liang, Y.; Ren, T.; Xu, L. Antisense oligonucleotide treatment enhances the recovery of acute lung injury through IL-10-secreting M2-like macrophage-induced expansion of CD4+ regulatory T cells. J. Immunol. 2013, 190, 4337–4348. [CrossRef]

96. Goodwin, A.J.; Li, P.; Halushka, P.V.; Cook, J.A.; Sumal, A.S.; Fan, H. Circulating miRNA 887 is differentially expressed in ARDS and modulates endothelial function. Am. J. Physiol. Lung Cell. Mol. Physiol. 2020, 318, L1261–L1269. [CrossRef]

97. Ke, X.F.; Fang, J.; Wu, X.N.; Yu, C.H. MicroRNA-203 accelerates apoptosis in LPS-stimulated alveolar epithelial cells by targeting PIK3CA. Biochem. Biophys. Res. Commun. 2014, 450, 1297–1303. [CrossRef]

98. Janku, F.; Hong, D.S.; Fu, S.; Piha-Paul, S.A.; Naing, A.; Falchook, G.S.; Tsimberidou, A.M.; Stepanek, V.M.; Moulder, S.L.; Ju, M.; Liu, B.; He, H.; Gu, Z.; Liu, Y.; Su, Y.; Zhu, D.; Cang, J.; Luo, Z.; et al. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014, 6, 377–387. [CrossRef]

99. Li, W.; Qiu, X.; Liu, J.; Han, Y.; Wei, D.; Ji, G.; Jiang, H. MiR-27a protects against acute lung injury in LPS-treated mice by inhibiting NF-κB-mediated inflammatory response. Int. J. Clin. Exp. Pathol. 2018, 11, 2980–2989.

100. Liu, Q.; Zhang, W.K. Advances in the mechanism of microRNAs regulating acute lung injury in sepsis. Clin. Med. China 2021, 37, 280–284.

101. Ju, M.; Liu, B.; He, H.; Gu, Z.; Liu, Y.; Su, Y.; Zhu, D.; Cang, J.; Luo, Z. MicroRNA-27a alleviates LPS-induced acute lung injury in mice via inhibiting inflammation and apoptosis through modulating TLR4/MyD88/NF-κB pathway. Cell Cycle 2018, 17, 2001–2018. [CrossRef]

102. Yang, Y.; Yang, F.; Yu, X.; Wang, B.; Yang, Y.; Zhou, X.; Cheng, R.; Xia, S.; Zhou, X. miR-16 inhibits NLRP3 inflammasome activation by directly targeting TLR4 in acute lung injury. Biomed. Pharmacother. 2019, 112, 108664. [CrossRef] [PubMed]

103. Yang, J.; Chen, Y.; Jiang, K.; Zhao, G.; Guo, S.; Liu, J.; Yang, Y.; Deng, G. MicroRNA-182 supplies negative feedback regulation to ameliorate lipopolysaccharide-induced ALI in mice by targeting TLR4. J. Cell. Physiol. 2020, 235, 5925–5937. [CrossRef] [PubMed]

104. Zeng, Z.; Gong, H.; Li, Y.; Jie, K.; Ding, C.; Shao, Q.; Liu, F.; Zhan, Y.; Nie, C.; Zhu, W.; et al. Upregulation of miR-146a contributes to the suppression of inflammatory responses in LPS-induced acute lung injury. Exp. Lung Res. 2013, 39, 275–282. [CrossRef] [PubMed]

105. He, R.; Li, Y.; Zhou, L.; Su, X.; Li, Y.; Pan, P.; Hu, C. MiR-146b overexpression ameliorates lipopolysaccharide-induced acute lung injury in vivo and in vitro. J. Cell. Biochem. 2017, 120, 2929–2939. [CrossRef] [PubMed]

106. Liang, Y.; Xie, J.; Che, D.; Zhang, C.; Lin, Y.; Feng, L.; Chen, J.; Chen, J.; Chen, L.; Wu, Z. MiR-124-3p helps to protect against acute respiratory distress syndrome by targeting p65. Biosci. Rep. 2020, 40, BSR20191232. [CrossRef] [PubMed]

107. Sun, X.; Icli, B.; Wara, A.K.; Belkin, N.; He, S.; Kobzik, L.; Hunninghake, G.M.; Vera, M.P.; Blackwell, T.S.; Baron, R.M.; et al. MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J. Clin. Investig. 2012, 122, 1973–1990. [CrossRef]

108. Wang, Y.; Mao, G.; Lv, Y.; Huang, Q.; Wang, G. MicroRNA-181b stimulates inflammation via the nuclear factor-κB signaling pathway in vitro. Exp. Ther. Med. 2015, 10, 1584–1590. [CrossRef]

109. Hayden, M.S.; Ghosh, S. NF-κB, the first quarter-century: Remarkable progress and outstanding questions. Genes Dev. 2012, 26, 203–234. [CrossRef]

110. Yang, H.; Lu, Z.; Huo, C.; Chen, Y.; Cao, H.; Xie, P.; Zhou, H.; Liu, D.; Liu, J.; Yu, L. Liang-Ge-San, a Classic Traditional Chinese Medicine Formula, Attenuates Lipopolysaccharide-Induced Acute Lung Injury Through Up-Regulating miR-21. Front. Pharmacol. 2019, 10, 1332. [CrossRef]

111. Kong, F.; Sun, Y.; Song, W.; Zhou, Y.; Zhu, S. MiR-216a alleviates LPS-induced acute lung injury via regulating JAK2/STAT3 and NF-κB signaling. Hum. Cell 2020, 33, 67–78. [CrossRef]

112. Zhou, T.; Chen, Y.L. The Functional Mechanisms of miR-30b-5p in Acute Lung Injury in Children. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2019, 25, 40–51. [CrossRef]

113. Chaves de Souza, J.A.; Nogueira, A.V.; Chaves de Souza, P.P.; Kim, Y.J.; Silva Lobo, C.; Pimentel Lopes de Oliveira, G.J.; Cirelli, J.A.; Garlet, G.P.; Rossa, C., Jr. SOCS3 expression correlates with severity of inflammation, expression of proinflammatory cytokines, and activation of STAT3 and p38 MAPK in LPS-induced inflammation in vivo. Mediat. Inflamm. 2013, 2013, 650812. [CrossRef] [PubMed]

114. Xie, T.; Liang, J.; Liu, N.; Wang, Q.; Li, Y.; Noble, P.W.; Jiang, D. MicroRNA-127 inhibits lung inflammation by targeting IgG Fc receptor I. J. Immunol. 2012, 188, 2437–2444. [CrossRef] [PubMed]
115. Coll, R.C.; Robertson, A.A.; Chae, J.J.; Higgins, S.C.; Muñoz-Planillo, R.; Inserra, M.C.; Vetter, I.; Dungan, L.S.; Monks, B.G.; Stutz, A.; et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015, 21, 248–255. [CrossRef] [PubMed]

116. You, Q.; Wang, J.; Jia, D.; Jiang, L.; Chang, Y.; Li, W. MiR-802 alleviates lipopolysaccharide-induced acute lung injury by targeting Peli2. Inflamm. Res. 2020, 69, 75–85. [CrossRef] [PubMed]

117. Humphries, F.; Bergin, R.; Jackson, R.; Delagic, N.; Wang, B.; Yang, S.; Dubois, A.V.; Ingram, R.J.; Moynagh, P.N. The E3 ubiquitin ligase Pellino2 mediates priming of the NLRP3 inflammasome. Nat. Commun. 2018, 9, 1560. [CrossRef]

118. Haneklaus, M.; Gerlic, M.; Kurowska-Stolarska, M.; Rainey, A.A.; Pich, D.; McCluskey, I.; Hammerschmidt, W.; O’Neill, L.A.; Masters, S.L. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1β production. J. Immunol. 2012, 189, 3795–3799. [CrossRef]

119. Xu, F.; Zhou, F. Inhibition of microRNA-92a ameliorates lipopolysaccharide-induced endothelial barrier dysfunction by targeting ITGA5 through the PI3K/Akt signaling pathway in human pulmonary microvascular endothelial cells. Int. Immunopharmacol. 2020, 78, 106060. [CrossRef]

120. Zhou, Y.; Yang, Y.; Liang, T.; Hu, Y.; Tang, H.; Song, D.; Fang, H. The regulatory effect of microRNA-21a-3p on the promotion of telocyte angiogenesis mediated by PI3K (p110α)/AKT/mTOR in LPS induced mice ARDS. J. Transl. Med. 2019, 17, 427. [CrossRef]

121. Shah, D.; Das, P.; Alam, M.A.; Mahajan, N.; Romero, F.; Shahid, M.; Singh, H.; Bhandari, V. MicroRNA-34a Promotes Endothelial Dysfunction and Mitochondrial-mediated Apoptosis in Murine Models of Acute Lung Injury. Am. J. Resp. Cell Mol. Biol. 2019, 60, 465–477. [CrossRef]

122. Fang, Y.; Gao, F.; Hao, J.; Liu, Z. microRNA-1246 mediates lipopolysaccharide-induced pulmonary endothelial cell apoptosis and acute lung injury by targeting angiotsenin-converting enzyme 2. Am. J. Transl. Res. 2017, 9, 1287–1296. [PubMed]

123. Xie, W.; Lu, Q.; Wang, K.; Lu, J.; Gu, X.; Zhu, D.; Liu, F.; Guo, Z. miR-34b-5p inhibition attenuates sepsis-induced acute lung injury by targeting SIRT1. J. Cell. Physiol. 2018, 233, 6615–6631. [CrossRef] [PubMed]

124. Liu, Y.; Guan, H.; Zhang, J.L.; Zheng, Z.; Wang, H.T.; Tao, K.; Han, S.C.; Su, L.L.; Hu, D. Acute downregulation of miR-199a attenuates sepsis-induced acute lung injury by targeting SIRT1. Am. J. Physiol. Cell Physiol. 2018, 314, C449–C455. [CrossRef] [PubMed]

125. Liu, Y.; Guan, H.; Zhang, J.L.; Zheng, Z.; Wang, H.T.; Tao, K.; Han, S.C.; Su, L.L.; Hu, D. Acute downregulation of miR-199a attenuates sepsis-induced acute lung injury by targeting SIRT1. Am. J. Physiol. Cell Physiol. 2018, 314, C449–C455. [CrossRef] [PubMed]

126. Li, X.; Wang, J.; Wu, H.; Guo, P.; Wang, C.; Yang, Z. Reduced peripheral blood miR-140 may be a biomarker for acute lung injury by targeting Toll-like receptor 4 (TLR4). Exp. Ther. Med. 2018, 16, 3632–3638. [PubMed]

127. Yang, Y.; Liu, D.; Xi, Y.; Li, J.; Liu, B.; Li, J. Upregulation of miRNA-140-5p inhibits inflammatory cytokines in acute lung injury through the MyD88/NF-kB signaling pathway by targeting TLR4. Exp. Ther. Med. 2018, 16, 3913–3920. [CrossRef]

128. McDonald, M.K.; Tian, Y.; Qureshi, R.A.; Gormley, M.; Ertel, A.; Gao, R.; Aradillas Lopez, E.; Alexander, G.M.; Sacan, A.; Fortina, P.; et al. Functional significance of macrophage-derived exosomes in inflammation and pain. Pain 2014, 155, 1527–1539. [CrossRef] [PubMed]

129. Cao, X.; Zhang, C.; Zhang, X.; Chen, Y.; Zhang, H. MiR-145 negatively regulates TGFB2 signaling responsible for sepsis-induced acute lung injury. Biomed. Pharmacother. 2019, 111, 852–858. [CrossRef]

130. Yi, X.; Wei, X.; Ly, H.; An, Y.; Li, L.; Lu, P.; Yang, Y.; Zhang, Q.; Yi, H.; Chen, G. Exosomes derived from microRNA-30b-5p-overexpressing mesenchymal stem cells protect against lipopolysaccharide-induced acute lung injury by inhibiting SAA3. Exp. Cell Res. 2019, 383, 111454. [CrossRef]

131. Quan, Y.; Wang, Z.; Gong, L.; Peng, X.; Richard, M.A.; Zhang, J.; Fornage, M.; Alcorn, J.L.; Wang, D. Exosome miR-371b-5p promotes proliferation of lung alveolar progenitor type II cells by using PTEN to orchestrate the PI3K/Akt signaling pathway in human pulmonary microvascular endothelial cells. J. Transl. Med. 2019, 17, 1287–1296. [PubMed]

132. Ye, C.; Li, H.; Bao, M.; Zhuo, R.; Jiang, G.; Wang, W. Alveolar macrophage-derived exosomes modulate severity and outcome of acute lung injury. Aging 2020, 12, 6120–6128. [CrossRef] [PubMed]

133. Rupaimoole, R.; Slack, F.J. MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat. Rev. Drug Discov. 2017, 16, 203–222. [CrossRef] [PubMed]

134. He, C.Z.; Song, J.L.; Hu, S.D.; Teng, D.; Du, X.H. Advances in clinical trials of miRNAs for tumor diagnosis and treatment. J. People’s Lib. Army Med. Coll. 2020, 41, 1265–1269. [CrossRef]

135. Bartel, D.P. Metazoan MicroRNAs. Cell 2004, 117, 20–51. [CrossRef]
139. Wiemer, E.A.C.; Wozniak, A.; Burger, H.; Smid, M.; Floris, G.; Nzkirantevye, A.; Sciot, R.; Sleijfer, S.; Schöffski, P. Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. *Eur. J. Cancer* 2017, 75, 33–40. [CrossRef]

140. van der Ree, M.H.; de Vree, J.M.; Stelma, F.; Willemse, S.; van der Valk, M.; Rietdijk, S.; Molenkamp, R.; Schinkel, J.; van Nuenen, A.C.; Beuers, U.; et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: A phase 1B, double-blind, randomised controlled trial. *Lancet* 2017, 389, 709–717. [CrossRef]

141. Bader, A.G. miR-34—a microRNA replacement therapy is headed to the clinic. *Front. Genet.* 2012, 3, 120. [CrossRef]

142. Beg, M.S.; Brenner, A.J.; Sachdev, J.; Borad, M.; Kang, Y.K.; Stoudemire, J.; Smith, S.; Bader, A.G.; Kim, S.; Hong, D.S. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. *Investig. New Drugs* 2017, 35, 180–188. [CrossRef] [PubMed]

143. Misso, G.; Di Martino, M.T.; De Rosa, G.; Farooqi, A.A.; Lombardi, A.; Campani, V.; Zarone, M.R.; Gullà, A.; Tagliaferri, P.; Tassone, P.; et al. Mir-34: A new weapon against cancer? *Mol. Ther. Nucleic Acids* 2014, 3, e194. [CrossRef] [PubMed]

144. Cortez, M.A.; Ivan, C.; Valdecanas, D.; Wang, X.; Peltier, H.J.; Ye, Y.; Araujo, L.; Carbone, D.P.; Shilo, K.; Giri, D.K.; et al. PDL1 Regulation by p53 via miR-34. *J. Natl. Cancer Inst.* 2016, 108, djv303. [CrossRef] [PubMed]

145. Stahlhut, C.; Slack, F.J. Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. *Cell Cycle* 2015, 14, 2171–2180. [CrossRef] [PubMed]

146. Seto, A.G.; Beatty, X.; Lynch, J.M.; Hermreck, M.; Tetzlaff, M.; Duvic, M.; Jackson, A.I. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma. *Br. J. Haematol.* 2018, 183, 428–444. [CrossRef] [PubMed]

147. Rayner, K.J.; Esau, C.C.; Hussain, F.N.; McDaniel, A.L.; Marshall, S.M.; van Gils, J.M.; Ray, T.D.; Sheedy, F.J.; Goedeke, L.; Liu, X.; et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. *Nature* 2011, 478, 404–407. [CrossRef]

148. Vickers, K.C.; Rader, D.J. Nuclear receptors and microRNA-144 coordinately regulate cholesterol efflux. *Circ. Res.* 2013, 112, 1529–1531. [CrossRef]

149. Wu, H.L.; Pu, Y.; Meng, X.P.; Cui, S.Y.; Tao, B.; Fan, S.Z.; Xu, L. Prospects for clinical treatment of heart disease based on microRNA. *J. Guangzhou Med. Univ.* 2021, 49, 130–136.

150. Wang, L.; Qin, D.; Shi, H.; Zhang, Y.; Li, H.; Han, Q. MiR-195-5p Promotes Cardiomyocyte Hypertrophy by Targeting MFN2 and FBXW7. *BioMed Res. Int.* 2019, 2019, 1580982. [CrossRef]

151. Zeng, M.; Sang, W.; Chen, S.; Chen, R.; Zhang, H.; Xue, F.; Li, Z.; Liu, Y.; Gong, Y.; Zhang, H.; et al. 4-PBA inhibits LPS-induced inflammation through regulating ER stress and autophagy in acute lung injury models. *Toxicol. Lett.* 2017, 271, 26–37. [CrossRef]

152. Rajasekaran, S.; Pattarayan, D.; Rajaguru, P.; Sudhakar Gandhi, P.S.; Thimmulappa, R.K. MicroRNA Regulation of Acute Lung Injury and Acute Respiratory Distress Syndrome. *J. Cell. Physiol.* 2016, 231, 2097–2106. [CrossRef] [PubMed]